Guidelines for Estradiol Therapy in Postmenopausal Vasomotor Symptoms
Transdermal Estradiol Advantages
- Transdermal estradiol avoids first‑pass hepatic metabolism, which may lower cardiovascular and thrombotic risk compared with oral estradiol in women with moderate‑to‑severe vasomotor symptoms. 1
Age‑Specific Cardiovascular Recommendations
Women ≤ 59 years or < 10 years since menopause
- Initiate estrogen‑only therapy (ET) for women without a uterus or estrogen‑plus‑progestogen therapy (EPT) for women with an intact uterus, provided there are no contraindications or excess cardiovascular/breast‑cancer risk. 1
Women 60–69 years or ≥ 10 years since menopause
- Perform baseline cardiovascular disease (CVD) risk assessment before starting hormone therapy. 1
- If CVD risk is moderate, prefer transdermal estradiol combined with micronized progesterone (or another metabolically neutral progestogen) because transdermal formulations have fewer adverse metabolic effects. 1
Safety Monitoring
- Any postmenopausal bleeding, regardless of hormone regimen, requires immediate evaluation with transvaginal ultrasound and/or endometrial sampling to exclude hyperplasia or malignancy. 1
- Patients should be counseled that estrogen‑plus‑progestogen therapy may increase breast‑cancer risk during use and after discontinuation; age‑appropriate breast‑cancer screening must be maintained. 1
- The decision to continue hormone therapy should be revisited at least annually, aiming for the shortest total duration consistent with treatment goals. 1
- In women with high CVD risk, non‑hormonal options (e.g., SSRIs/SNRIs such as paroxetine or venlafaxine) should be offered instead of systemic estrogen. 1
Progestogen Requirement for an Intact Uterus
- Unopposed estrogen raises endometrial cancer risk 2.1‑ to 5.7‑fold; therefore a progestogen must be added to all systemic estrogen regimens in women with a uterus. 2
First‑Line Progestogen Regimen
| Regimen | Dose & Route | Schedule | Key Points |
|---|---|---|---|
| Micronized progesterone (MP) | 200 mg orally or vaginally | 12–14 consecutive days per 28‑day cycle (sequential) | Lower cardiovascular and venous thromboembolism risk than synthetic progestins; provides adequate endometrial protection. [2] |
| Withdrawal bleeding typically occurs 2–7 days after the last dose. [2] |
Alternative Progestogen Options (when MP unavailable)
| Progestogen | Sequential Dose (12–14 days/month) | Continuous Dose | Notes |
|---|---|---|---|
| Medroxyprogesterone acetate (MPA) | 10 mg daily | 2.5 mg daily | |
| Dydrogesterone | 10 mg daily | 5 mg daily | |
| Norethisterone | — | ≥1 mg daily |
- Progestogen exposure must not be shortened below 10 days per month; shorter courses fail to protect the endometrium. 2
- Continuous daily progesterone is discouraged because it is associated with increased breast‑cancer risk (Grade D recommendation). 2
Transdermal Combination Patches
- Sequential patch: 50 µg estradiol daily for 2 weeks, then 50 µg estradiol + 10 µg levonorgestrel daily for the next 2 weeks. 2
- Continuous patch: 50 µg estradiol + 7 µg levonorgestrel daily without interruption, eliminating withdrawal bleeding. 2
Decision Algorithm Highlights
- 50–59 years or < 10 years post‑menopause → proceed to therapy initiation. 1
- 60–69 years or ≥ 10 years post‑menopause → evaluate CVD risk; if moderate, choose transdermal estradiol. 1
- ≥ 70 years → do not initiate hormone therapy.
Special Populations
- Women with primary ovarian insufficiency or premature menopause should continue hormone therapy until the expected age of natural menopause (≈ 51 years), then reassess. 1